CDMO Serán sets out to build first commercial facility, with a $200M investment led by Bain Capital

Small molecule contract manufacturer Serán Bioscience is building its first commercial-scale manufacturing facility, backed by a $200 million investment from Bain Capital and others. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

EU pharma legislation may bring ‘more harm than good’ to the region

Reform of the EU pharmaceutical legislation was launched in April by the European Commission. Credit: New Africa via Shutterstock. Debates across Europe are needed to

November 7, 2023

Immunomodulatory effects of PFAS can impair health

Because they are persistant, per- and polyfluoroalkyl substances (PFAS) are also known as “chemicals for eternety”.

July 18, 2023

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to Handle Functional Unblinding; Doblin Charts a Future for MAPS; DEA Plots Ketamine Crackdown – Psychedelic Alpha

In this Issue Lykos CEO Provides AdComm Feedback to FDA Commissioner Cybin Plans to Fight Functional Unblinding with ‘Firewall’ Doblin Charts a Future for MAPS

August 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.